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Several experimental studies have shown a negative inﬂuence of benzodiazepines on driving skills. The objective of this study is to
study the relationship between the blood concentration of benzodiazepines and the inﬂuence on performance in ﬁeld sobriety tests.
A retrospective case ﬁle evaluation was conducted to select cases of drivers, tested positive for benzodiazepines only in the period from
January 1999 to December 2004. Drivers were grouped into the categories sub therapeutic, therapeutic or elevated concentrations. The
outcome of the tests (walking, walking after turn, nystagmus, Romberg’s test, behavior, pupils and orientation) was binomial. A Chi
square test was used to assess diﬀerences in proportions of the categorized cases.
In total 171 cases were included. Observations of behavior (n = 137; p < 0.01), walking (n = 109; p < 0.01), walking after turn (n = 89;
p = 0.02) and Romberg’s test (n = 88; p < 0.05) were signiﬁcantly related to the benzodiazepine concentration. There was no signiﬁcant
relation between benzodiazepine concentration and eﬀect on pupil size, nystagmus or orientation.
The results of our study indicate a relation between the concentration of benzodiazepines and the results of some performance tests.
More eﬀort is needed to standardize the tests and to determine the sensitivity and selectivity of the tests for benzodiazepines.
 2008 Elsevier Ltd and FFLM. All rights reserved.
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Several experimental studies have shown a negative
inﬂuence of benzodiazepines on driving skills.1–3 In addi-
tion, epidemiological studies have shown an association
between benzodiazepine use and accident risk although
the results of those studies have not always been consistent.
Some studies suggest a relationship between blood concen-
trations of benzodiazepines and accident risk.4,5 Until now,
little information is available about the relation between
blood concentration of benzodiazepines and the inﬂuence
on standardized ﬁeld sobriety tests. A study of Bramness1752-928X/$ - see front matter  2008 Elsevier Ltd and FFLM. All rights res
doi:10.1016/j.jﬂm.2008.04.002
* Corresponding author. Tel.: +31 70 888 66 11; fax +31 70 888 65 51.
E-mail address: b.smink@nﬁ.minjus.nl (B.E. Smink).et al.6 suggested a dose-dependent impairment and as a
consequence increased accident risk by benzodiazepines.
In The Netherlands, a suspicion of driving under the
inﬂuence of psychoactive substances other than ethanol is
obtained by deviant driving behavior or by observations
from the police. A blood or urine sample can be taken from
the driver by a physician and sent to the Netherlands
Forensic Institute (NFI) by the police oﬃcer for toxicolog-
ical analysis. On the request form for toxicological investi-
gation, information should be ﬁlled in concerning
performance of the driver while walking on line, walking
on line after turn and standing on one leg for 30 s with
eyes closed (Romberg’s test). In addition observations
concerning orientation (in time, place and person),
nystagmus, behavior and pupil size are requested. Theerved.
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purposes at this moment, but when performed, the results
can be used to detect signs of impairment possibly related
to the use of psychoactive substances which may result in
the decision to take a blood sample.
The results of the toxicological analysis and an interpre-
tation of the results with regard to driving performance are
returned to the police. For ethanol in blood a legal limit is
in force, based on the well established relationship between
blood alcohol concentration and accident risk.7 For other
substances, no limits are laid down in the Dutch Road
Traﬃc Act.8 The police report with the toxicological report
is sent to one of the nineteen district courts in The Nether-
lands. Depending on the case, prosecution may involve a
single judge chamber (police judge) or a full bench of three
judges (more serious cases). All information relevant to the
case is ﬁled.
The legal procedure could be simpliﬁed if legal limits
were available for other substances than ethanol.9 How-
ever, for benzodiazepines and other psychoactive sub-
stances, more information about the relationship between
dose, blood concentration and eﬀect is needed to establish
limits indicating impairment that are incompatible with
safe driving behavior. The objective of this retrospective
case ﬁle evaluation is to study the relationship between
the blood concentration of benzodiazepines and the inﬂu-
ence on performance in ﬁeld sobriety tests on drivers,




A retrospective review of the database of the Depart-
ment of Toxicology, NFI was conducted to select cases
of drivers suspected of driving under the inﬂuence of ben-
zodiazepines only in the period from January 1999 to
December 2004.
Cases were selected in which both a drug screening and a
speciﬁc analysis by using high performance liquid chroma-
tography in combination with UV diode array detection
were performed with positive results for benzodiazepines,
zopiclone or zolpidem only. The analytical strategy and
methods used in forensic case work at the NFI have been
described elsewhere.10 The drug classes included in the
screening were opiates, cocaine, methadone, ampheta-
mines, benzodiazepines, barbiturates, cannabinoids and
tricyclic antidepressants. In case of self-declared or sus-
pected use of other psychoactive substances a more exten-
sive screening was performed. The estimated cutoﬀ value
for benzodiazepines is around 0.01 mg/L for all benzodi-
azepines. Cases were excluded if the alcohol concentration
was higher than the legal limit (i.e. 220 lg/L breath or
0.5 mg/mL blood). If neither an evidential alcohol breath
test nor a blood alcohol test was performed, it was assumed
that the driver passed the preliminary breath test or thatthere was no suspicion for alcohol use and that the alcohol
concentration was lower than or equal to the legal limit.
Data collected, relevant to this study were case identiﬁca-
tion numbers, age and gender of the driver, relevant toxico-
logical data (analytical results, self-declared or suspected
drug use) and the results of the ﬁeld sobriety tests per-
formed (i.e. walking, walking after turn, nystagmus, Rom-
berg’s test, behavior, pupils, orientation).
Approval from the Board of prosecutors-general, head
of the prosecution service was obtained to perform this
study.
2.2 Blood concentrations
Reference plasma or serum concentrations of the benzo-
diazepines detected were derived from literature.11–13
However, the NFI measured the concentrations of benzo-
diazepines in whole blood. In general, the plasma to whole
blood ratio has been published for many substances. With
respect to benzodiazepines, the plasma to whole blood
ratios has been published only for a limited number of
substances (i.e. alprazolam, diazepam, nordazepam, oxaze-
pam, temazepam, zopiclone).12,14 For these compounds,
reference plasma concentrations were converted to
whole blood concentrations. In all other cases, plasma
concentrations were deﬁned to be equal to whole blood
concentrations.
In order to relate the measured blood concentrations to
the reference concentrations in blood, the measured values
were expressed as the proportion of the average therapeutic
concentration. This means that the measured blood con-
centration of a substance was divided by the mean of the
lower and upper limit of the therapeutic range as men-
tioned in Table 1. If more than one substance (parent drug
or metabolite) were detected in one blood sample the pro-
portions were added up. The sum was grouped into one of
the three mutually exclusive categories (a) sub therapeutic
concentrations (sum lower than or equal to 0.35) (b) ther-
apeutic concentrations (sum 0.35–1.65) or (c) elevated con-
centrations (sum higher than 1.65).
The thresholds of 0.35 and 1.65 are based on the ratios
of the lower limit of the therapeutic range to the mean ther-
apeutic concentration for all substances mentioned in
Table 1 (mean 0.35; median 0.40; range 0.00–0.81) and
the ratios of the upper limit of the therapeutic range to
the mean therapeutic concentrations (mean 1.65; median
1.60; range 1.19–2.00), respectively.
Another approach has also been tested: blood concen-
trations of the substances detected were expressed as the
proportion of the upper limit of the therapeutic range, as
described in Table 1. If more than one substance were
detected in one blood sample, the proportions were added
up. Cases were grouped into three mutually exclusive cate-
gories (low, therapeutic, elevated concentrations). If the
sum of the proportions was lower than or equal to 0.25,
the case was grouped into the category ‘‘low concentra-
tions”. The threshold of 0.25 was based on the lower limit
Table 1

























a Substances screened for but not detected are hydroxy-alprazolam,
brotizolam, acetamidoclonazepam, acetamidonitrazepam, ﬂunitrazepam,
aminoﬂunitrazepam, desmethylﬂunitrazepam, ﬂurazepam, ketazolam,
loprazolam, desmethylmedazepam, triazolam, hydroxy-midazolam.
b Concentrations of the metabolite have been added to the concentration
of the parent drug since therapeutic reference values for the metabolite are
missing.
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listed in Table 1 (median 0.25; mean 0.24; range 0.00–
0.68). If the sum of the proportions was higher than 1,
the case was grouped into the category ‘‘elevated
concentrations”.
2.3 Observations and results of the ﬁeld sobriety tests
The ﬁeld sobriety tests were focused on alertness (orien-
tation, behavior), balance control and motor function
(Romberg’s test, walking, walking after turn) and ocular
side eﬀects of drugs (nystagmus, pupil size). Test observa-
tions were done by the physician who collected the blood
sample or by the police oﬃcer. According to the form of
request, observations with regard to walking, walking after
turn and orientation were classiﬁed into the categories ‘‘not
impaired”, ‘‘uncertain”, and ‘‘impaired”. Nystagmus was
classiﬁed as ‘‘negative” or ‘‘positive”. Behavior was scored
as ‘‘self-controlled”, ‘‘unrestrained” or ‘‘sedated”. Pupil
size was classiﬁed into the categories ‘‘normal”, ‘‘large”
or ‘‘small”. Romberg’s test was classiﬁed as ‘‘negative”,
‘‘uncertain” or ‘‘positive” (i.e. not completed or disturbed).
In practice, the information requested was not always
provided. Injured drivers might not be able to perform
the tests and circumstances might contribute to non-
response (time of day, weather, failure to appreciate thebeneﬁts of the tests by the police or the physician). Results
were classiﬁed as ‘‘not observed/not performed” if test
results were missing on the form and if it was documented
that the tests could not be performed. If it was not clear
why observations or test results were missing on the form,
the results were classiﬁed as ‘‘not documented”.
2.4 Data analysis
Test results were excluded if the results of the perfor-
mance testswere ‘‘not observed/not performed”or ‘‘not doc-
umented”. The outcome of the tests in this study was
binomial: ‘‘not impaired/uncertain” or ‘‘impaired” (walk-
ing, walking after turn, orientation), ‘‘negative” or
‘‘positive” (nystagmus), ‘‘self-controlled/unrestrained” or
‘‘sedated” (behavior), ‘‘normal” or ‘‘large or small” (pupil
size) or ‘‘negative” or ‘‘positive” (Romberg’s test).
A Chi square test was used to assess diﬀerences in pro-
portions of the categorized cases.
To make the Chi square test valid for nystagmus and
orientation, the subtherapeutic and the therapeutic groups
were combined. A probability greater than 5% was deﬁned
to be non-signiﬁcant. The relation between concentrations
of benzodiazepine, zopiclone and zolpidem and perfor-
mance was analyzed using SPSS 15.0 statistical software.3. Results
3.1 Study population
In total 171 cases were included. Age and gender were
documented of 169 and 136 drivers, respectively. Male
drivers represented at least 53% (91/171) of the group. At
least 50% (85/171) of the drivers was involved in an acci-
dent according to the information on the form of request
for toxicological analysis.
3.2 Blood concentrations
Table 2 shows the substances detected in drivers sus-
pected of driving under the inﬂuence and tested positive
for benzodiazepines, zopiclone or zolpidem only. The most
frequently detected benzodiazepines were oxazepam (46%;
78/171), nordazepam (37%; 64/171), temazepam (29%; 49/
171) and diazepam (24%; 42/171).
3.3 Relation between blood concentration and performance
Fig. 1 shows the percentage of impaired drivers for each
test within each (relative) concentration category (subther-
apeutic, therapeutic, elevated concentrations of benzodi-
azepines). The measured blood concentrations are related
to the mean of the therapeutic range, as described under
methods.
Observations of behavior, walking, walking after turn
and Romberg’s test were signiﬁcantly related to the con-
Table 2
Benzodiazepines detected in drivers suspected of driving under the
inﬂuence of benzodiazepines only (n = 171)
Substance n Blood concentration (mg/L)
Mean Median Min Max
Alprazolam 1 0.03 0.03 0.03 0.03
Bromazepam 4 0.42 0.33 0.08 0.96
OH-bromazepam 2 0.05 0.05 0.03 0.06
Chlordiazepoxide 7 2.79 0.82 0.16 11.00
Norchlordiazepoxide 5 1.21 0.63 0.34 2.68
Demoxepam 7 1.66 0.72 0.10 3.80
Clobazam 1 0.33 0.33 0.33 0.33
Norclobazam 1 1.89 1.89 1.89 1.89
Clonazepam 3 0.06 0.05 0.02 0.12
7-Aminoclonazepam 1 0.02 0.02 0.02 0.02
Flurazepam n.d.
Desalkylﬂurazepam 8 0.06 0.04 0.01 0.24
OH-ethylﬂurazepam 1 0.09 0.09 0.09 0.09
Lorazepam 8 0.16 0.09 0.01 0.49
Lormetazepam 7 0.03 0.02 0.01 0.05
Midazolam 4 0.05 0.05 0.02 0.09
OH-midazolam 2 0.03 0.03 0.01 0.04
Nitrazepam 3 0.08 0.10 0.01 0.12
Diazepam 42 0.33 0.22 0.01 3.00
Nordazepam 64 0.48 0.25 0.01 3.70
Oxazepam 78 0.95 0.46 0.01 7.10
Temazepam 49 0.47 0.15 0.01 2.80
Zolpidem 9 0.26 0.24 0.04 0.68
Zopiclone 3 0.15 0.09 0.05 0.30
n.d. = not detected.
Note: substances screened for but not detected are hydroxy-alprazolam,
brotizolam, acetamidoclonazepam, acetamidonitrazepam, ﬂunitrazepam,
aminoﬂunitrazepam, desmethylﬂunitrazepam, ﬂurazepam, ketazolam,
loprazolam, desmethylmedazepam, triazolam, hydroxy-midazolam.
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blood concentrations of benzodiazepines and pupil size,
nystagmus or orientation could not be concluded.
The total number of observations for the diﬀerent tests
varied between 88 and 137.
The percentages of tests ‘‘not tested/not performed” (i.e.
the driver was unable to perform the test) and the percent-0%
50%
100%
Walking impaired (n=109; p
Behavior sedated (n=137; p<0.01)
Pupils large or small (n=123; N.S.)
Orientation impaired (n=117; N.S.)
Fig. 1. The percentage of impaired drivers for the performance tage ‘‘not documented” (i.e. information is missing) were for
walking 24% (41/171) and 12% (21/171), for walking after
turn 26% (45/171) and 22% (37/171), for nystagmus 12%
(21/171) and 12% (20/171), for Romberg’s test 29% (50/
171) and 19% (33/171), for behavior 13% (23/171) and
6% (11/171), for pupils 12% (21/171) and 16% (27/171),
and for orientation 16% (28/171) and 15% (26/171),
respectively.
Relating the measured blood concentration to the upper
limit of the therapeutic range instead of the average thera-
peutic concentration, yielded similar results (data are not
presented).
4. Discussion
The results of our study indicate that increasing concen-
trations of benzodiazepines (grouped into the categories
sub therapeutic, therapeutic and elevated) have an increas-
ingly negative inﬂuence on behavior, walking, walking
after turn and Romberg’s test. There was no signiﬁcant
relation between concentration benzodiazepine and eﬀect
on pupil size, nystagmus or disturbed orientation.
Our results are for the greater part in agreement with the
ﬁndings of Bramness et al. who found that 13 clinical sub-
tests and observations for impairment were related to
blood benzodiazepine concentration e.g. Romberg’s test,
walk and turn on line, and an observation regarding
appearance.6 However, our results did not conﬁrm the rela-
tion between benzodiazepine concentration and orientation
for time and place. A correlation between benzodiazepine
concentration and performance has also been demon-
strated by Kuitunen et al.15 Their results suggest that a test
battery of 13 tests was sensitive to acute benzodiazepine
eﬀects in a concentration-dependent way. Tolerance may
have inﬂuenced the test results in chronic diazepam users.
In addition, Longo et al. provided evidence of increased
vehicle crash culpability associated with benzodiazepine
use in a concentration-dependent way.4<0.01)
Walking after turn impaired (n=89, p=0.02)
Nystagmus positive (n=130; N.S.)




ests related to the relative concentrations of benzodiazepines.
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centrations as described under methods, is based on the
assumption that the additive eﬀects of substances with
the same pharmacological action may lead to adverse
eﬀects (e.g. impairment) even though the individual con-
centrations of the substances are sub therapeutic them-
selves. Longo et al. used a similar approach: they
established a scale of benzodiazepine concentrations using
the proportion of the Cmax for standard therapeutic doses
obtained from published sources (drug free, <0.26, 0.26–
1.0 or >1.0). Both approaches are liable to individual dif-
ferences in pharmacokinetics. Assuming that chronic use
of benzodiazepines is more common than incidental use
in the general driver population, classiﬁcation on basis
of steady state concentrations might be preferred. Bram-
ness et al. grouped the benzodiazepines in the classes
‘‘mildly”, ‘‘moderately” or ‘‘highly elevated” drug concen-
tration levels according to clinical experience, which is
expected to be in line with population based reference val-
ues published in literature. Diﬀerences can be explained by
e.g. variation in prescription pattern and the comparison
of plasma reference values with whole blood measure-
ments in the clinic.
Some factors limit the conclusions to be drawn from this
study. No diﬀerentiation has been made between the ben-
zodiazepines, although it is known that benzodiazepines
might diﬀer with respect to residual eﬀects and accident
risk.1,2,16,17 Information about chronic or single dose
intake was missing although it is known that tolerance
may inﬂuence test results. Another inﬂuencing factor might
have been confounding by indication. Information about
the case history was missing. In patients with renal failure,
metabolites can accumulate, inﬂuencing the dose – concen-
tration – eﬀect relationship. For example, accumulation of
the pharmacologically active conjugated hydroxymidazo-
lam in serum has been described in the absence of unconju-
gated midazolam or hydroxymidazolam.18 Failure rate of
the standardized ﬁeld sobriety tests in drivers not under
the inﬂuence of psychoactive substances is unknown.
However, the predictive value of some observations and
performance tests remains unclear. Friedel and Staak
reviewed the literature and concluded that sedative eﬀects
of benzodiazepines were seen in several studies although
subjective assessment of performance varied. Results of
studies in which the inﬂuence of benzodiazepines on body
sway has been examined varied from signiﬁcant improve-
ment, no signiﬁcant drug eﬀect to signiﬁcant impairment.3
Our results showed no signiﬁcant eﬀect of benzodiazepines
on nystagmus nor pupil size, although literature shows that
eye movements can be inﬂuenced by benzodiazepines.19,20
Benzodiazepines have been reported to modify nystagmus,
in a similar way as alcohol, and to inﬂuence saccadic move-
ments and smooth pursuit.20 It is not clear whether or not
our results may be explained by incorrect testing by the
police or the physician.
In case standardized ﬁeld sobriety tests will be required
to obtain a suspicion for impairment of drivers in order tojustify blood sampling for evidential blood testing, they
must have enough predictive value and robustness for use
in varying circumstances. This does not appear to be the
case. Another question is whether standardized ﬁeld sobri-
ety tests are sensitive enough to detect levels of all relevant
psychoactive substances suspected to impair driving or not.
Papafotiou et al. found a positive relationship between the
dose of THC administered (placebo, low and high dose,
respectively) and the number of healthy participants classi-
ﬁed as impaired based on the same standardized ﬁeld sobri-
ety tests.21,22 However, Silber et al. concluded that the
horizontal gaze nystagmus test, the walk and turn test
and the one leg stand test were not sensitive enough to
detect the presence of low levels of amphetamine.23
Police oﬃcers and physicians have to appreciate the ben-
eﬁts of the tests in order to be motivated to perform the
tests. The robustness of these tests, and as a result appreci-
ation, can be improved by paying more attention to stan-
dardization. O’Keefe showed that a signiﬁcant percentage
of police surgeons in Strathclyde expressed concerns
regarding the standardized ﬁeld sobriety tests: the walk
and turn test and the one leg stand test in particular. It
has been suggested that poor performance on these tests
might be related to interfering factors such as dyslexia, dys-
praxia or extreme fatigue24, which may be revealed by
other tests.5. Conclusions
The results of our study indicate a relation between the
concentration of benzodiazepines (grouped into the catego-
ries sub therapeutic, therapeutic and elevated) and the
inﬂuence on behavior, walking, walking after turn and
Romberg’s test. There was no signiﬁcant relation between
benzodiazepine concentration and eﬀect on pupil size, nys-
tagmus or orientation. The percentage of not documented
test results in our study varied between 12% and 22%, indi-
cating that the aim of the test, the performance of the test
or the validity of the test may have been questioned. More
eﬀort is needed to standardize the tests in order to improve
robustness and to determine the sensitivity and selectivity
of the tests for the individual benzodiazepines.Acknowledgements
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